NL-OMON29407
Completed
Not Applicable
Three arm randomized parallel phase II/III study evaluating the efficacy and safety of the combinations Epirubicin and Taxotere (ET), Taxotere and Navelbine (TN) and Navelbine and Epirubicin (EN) as first line therapy in patients with metastatic breast cancer.
VU medical center.0 sites111 target enrollmentTBD
ConditionsMetastic breast cancer.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Metastic breast cancer.
- Sponsor
- VU medical center.
- Enrollment
- 111
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Histologically proven breast cancer at first diagnosis. At study entry histological or cytological proof of metastasis is required in case of a single metastatic target lesion.
- •Female metastatic breast cancer patients
- •Measurable disease or evaluable disease (bone metastases only allowed).
Exclusion Criteria
- •1\. Prior chemotherapy for metastatic disease.
- •2\. Locally advanced inoperable breast cancer (Stage III B) as only manifestation of the disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 3
A Phase III Study in Subjects With Mild to Moderate Psoriasis.Mild to Moderate PsoriasisNCT05249972Lipidor AB294
Completed
Phase 3
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPDChronic Obstructive Pulmonary DiseaseNCT01917331Chiesi Farmaceutici S.p.A.1,368
Unknown
Phase 3
RCT, Blinded, 2-Arm Efficacy Study of IP and Placebo in Patients With Chronic Pain Related to Osteoarthritis of the KneeDegenerative ArthritisNCT05318521Overseas Pharmaceuticals, Ltd.500
Withdrawn
Phase 3
Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.CD20-positive Follicular Lymphoma, With Low Tumour BurdenNCT04671420Shanghai Henlius Biotech
Active, not recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3Gaucher's Disease Type IIINCT05222906Sanofi43